Physician profile
Seth D Kirschner
NPI 1548554546
$26,449.96
in general payments reported to CMS, 2019-2025
45 companies · $4,271 in 2025
The $4,271 reported for 2025 was more than what 90% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,569 · 2020: $2,499 · 2021: $3,229 · 2022: $4,381 · 2023: $4,092 · 2024: $4,409 · 2025: $4,271.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $13K · Education: $171.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $12,601.01 |
| Education | $170.93 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $5,957.23 | 2019-2025 | |
| Janssen Biotech, INC. | $2,938.06 | 2019-2025 | Stelara, Tremfya, Simponi Aria |
| Takeda Pharmaceuticals U.S.A., INC. | $2,650.12 | 2019-2025 | Entyvio, Gattex, Eohilia |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $2,508.05 | 2019-2025 | Xifaxan, Plenvu, Trulance |
| Madrigal Pharmaceuticals | $848.55 | 2024-2025 | Rezdiffra, Resmetirom |
| Ardelyx, INC. | $791.93 | 2022-2025 | Ibsrela |
| Genzyme Corporation | $791.88 | 2022-2025 | |
| Gilead Sciences, INC. | $770.61 | 2019-2025 | |
| Celgene Corporation | $733.47 | 2021-2024 | Zeposia |
| Redhill Biopharma INC. | $716.53 | 2020-2023 | Talicia, Movantik, Aemcolo |
| E.R. Squibb & Sons, L.L.C. | $681.34 | 2021-2023 | Zeposia |
| Janssen Scientific Affairs, LLC | $614.45 | 2019-2025 | Tremfya |
| Lilly USA, LLC | $516.22 | 2023-2025 | Omvoh, Zepbound |
| Intercept Pharmaceuticals, INC. | $514.17 | 2019-2025 | Ocaliva |
| Pfizer INC. | $511.90 | 2019-2025 |
Show all 45 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Braintree Laboratories, INC. | $476.30 | 2019-2025 | Suflave, Sutab |
| Boston Scientific Corporation | $424.64 | 2019-2023 | Resolution 360 Ultra Clip, Resolution 360 Clip |
| Qol Medical, LLC | $419.33 | 2021-2025 | Sucraid, Sucraid |
| Celltrion USA INC. | $386.11 | 2023-2025 | Vegzelma, Zymfentra, Yuflyma |
| Regeneron Healthcare Solutions, INC. | $374.24 | 2022-2025 | Dupixent |
| Ironwood Pharmaceuticals, INC | $368.38 | 2019-2025 | Linzess |
| Aimmune Therapeutics, INC. | $318.21 | 2024-2025 | Zenpep |
| Ferring Pharmaceuticals INC. | $275.92 | 2019-2025 | Rebyota, Clenpiq |
| Phathom Pharmaceuticals, INC. | $214.71 | 2024 | Voquezna |
| Cumberland Pharmaceuticals, INC. | $189.72 | 2020-2023 | Kristalose |
| Nestle Healthcare Nutrition INC. | $180.04 | 2021-2023 | |
| Ucb, INC. | $175.71 | 2019-2021 | |
| Vivus LLC | $170.80 | 2021-2025 | Pancreaze, Qsymia |
| Evoke Pharma, INC. | $116.11 | 2021-2024 | Gimoti |
| Shire North American Group INC | $100.62 | 2019 | |
| Alfasigma USA, INC. | $88.08 | 2020-2021 | |
| Allergan, INC. | $86.11 | 2019-2020 | |
| Concordia Pharmaceuticals INC. | $82.87 | 2019 | |
| Fresenius Kabi USA, LLC | $74.63 | 2023-2024 | Idacio |
| Organon LLC | $73.46 | 2021-2024 | Renflexis |
| Biocon Biologics INC | $45.96 | 2025 | Yesintek |
| Endo Pharmaceuticals INC. | $38.97 | 2019-2021 | |
| Micro-Tech Endoscopy USA, INC. | $38.32 | 2022-2024 | Lesionhunter |
| Pharmacosmos Therapeutics INC. | $37.10 | 2022-2025 | Monoferric |
| Capsovision, INC. | $36.65 | 2023 | Capsocam Plus |
| Cook Medical LLC | $25.52 | 2020 | |
| Amgen INC. | $23.18 | 2023 | Amjevita |
| Mylan Institutional INC. | $22.45 | 2023 | Hulio |
| Shionogi INC | $22.23 | 2019 | |
| Vibrant Gastro, INC. | $19.08 | 2024 | Vibrant Starter Kit |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Seth Kirschner listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.